FDA Approves Landmark Cancer Therapy; Wilmot Positioned Among First to Offer It

UR Medicine ’s Wilmot Cancer Institute will be among the first sites in the world to offer CAR T-cell therapy —a new type of immunotherapy—to adults with aggressive lymphoma. The engineered gene therapy has been described as a revolutionary “living drug” and one of the most powerful cancer treatments to emerge in recent years.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news

Related Links:

Conclusion: Recovery of miR-139-5p suppressed the expression of c-Jun and thus reversed cisplatin-resistance in ovarian cancer.Cell Physiol Biochem 2018;51:129 –141
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Conclusion: Overall, we observed high levels of agreement between CODMR and CODDC for common causes of death in HL and BC patients. Observed discrepancies between CODMR and CODDC frequently occurred in the presence of late effects of treatment for HL. PMID: 30425583 [PubMed]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Clin Epidemiol Source Type: research
CONCLUSIONS: Caution is required when interpreting spatial distributions of patients, given inaccuracies in residential addresses and referral patterns to the hospital, and with HIV and other infections probable important confounders. Our study therefore shows that active case recruitment is required for accurate assessment of residential information. However, some findings on spatial distributions in the study warrant the continuation of efforts to develop a study protocol to investigate the possible link between uranium exposure in mining areas and haematological malignancies in residents. Disproportionately high inciden...
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
We report here that transformation of primary B cells by EBV leads to genome-wide activation of LTR enhancers and promoters. The activation of LTRs coincides with local DNA hypomethylation and binding by transcription factors such as RUNX3, EBF1, and EBNA2. The set of activated LTRs is unique to transformed B cells compared with other cell lines known to have activated LTRs. Furthermore, we found that LTR activation impacts the B cell transcriptome by up-regulating transcripts driven by cryptic LTR promoters. These transcripts include genes important to oncogenesis of Hodgkin lymphoma and other cancers, such as HUWE1/HECTH...
Source: Genome Research - Category: Genetics & Stem Cells Authors: Tags: RESEARCH Source Type: research
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. It is characterized by the accumulation of CD19+/CD5+ lymphocytes and can have variable outcomes. Richter syndrome (RS) is a lethal complication in CLL patients that results in aggressive B-cell lymphomas, and there are no tests to predict its occurrence. Because alterations in microRNA expression can predict the development and progression of several cancers, we investigated whether dysregulation of specific microRNAs can predict RS in CLL patients. Thus, we compared microRNA expression levels in samples from 49 CLL patients who later developed RS with ...
Source: Blood - Category: Hematology Authors: Tags: Lymphoid Neoplasia, Brief Reports Source Type: research
After Michael Fisher was diagnosed with lymphoma in March, the CEO of Cincinnati Children ’s Hospital took a leave of absence to begin cancer treatment.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Hairy Cell Leukemia;   Interleukin-3 Receptor Subunit Alpha Positive;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm;   R ecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hematologic Malignancy;   Recurrent Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report herein the case of an 80-year-old man who was referred for a biochemical recurrence of a high-risk prostate cancer. In addition to prostate cancer recurrence, 18F-choline allowed partial initial staging of an incidental diffuse large B-cell lymphoma which was further confirmed and staged using 18F-FDG and a biopsy. Two types of metabolic behavior were therefore identified using 18F-choline and 18F-FDG which corresponded to 2 different uptake patterns, that is, those of the prostate and lymphoma tumoral cell contingents.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
AbstractPurposeIn 2014, we published the qPET method to quantify fluorodeoxyglucose positron emission tomography (FDG ‐PET) responses. Analysis of the distribution of the quantified signals suggested that a clearly abnormal FDG‐PET response corresponds to a visual Deauville score (vDS) of 5 and high qPET values ≥ 2. Evaluation in long‐term outcome data is still pending. Therefore, we analyzed progression‐ free survival (PFS) by early FDG‐PET response in a subset of the GPOH‐HD2002 trial for pediatric Hodgkin lymphoma (PHL).Patients/MethodsPairwise FDG ‐PET scans for initial staging and early response asses...
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
This study aims to evaluate the relationship between macrophage polarization pattern in the tumor microenvironment and relative expression of miR-155 in EBV + DLBCLe and EBV-negative DLBCL patients. We studied 28 EBV + DLBCLe and 65 EBV-negative DLBCL patient s. Tumor-associated macrophages (TAM) were evaluated by expression of CD68, CD163 and CD163/CD68 ratio (degree of M2 polarization), using tissue microarray. RNA was extracted from paraffin-embedded tumor samples for miR-155 relative expression study. We found a significantly higher CD163/CD68 ratio in EBV + DLBCLe compared to ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Gene Therapy | Genetics | Lymphoma | Universities & Medical Training